lentivirus News
-
New patent application published!
Atelerix has received notification that its newest patent application has been published pertaining to the STORING AND/OR TRANSPORTING OF EXTRACELLULAR NUCLEIC ACIDS (WO 2022/101640). This application was made after the surprising observation that Atelerix’s hydrogel-encapsulation technology (in the form of SwabReady™) was able to extend the shelf life of free Coronavirus samples ...
By Atelerix Ltd
-
Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced it will hold a webinar entitled "Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors" on Thursday, April 28, 2022 at 8:00 AM EDT / 2:00 PM CET. In this fireside chat, Genenta is ...
-
Matica Biotechnology, Inc. Announces Master Research Agreement with Texas A&M
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a master research agreement with the Center for Innovation in Advanced Development and Manufacturing (CIADM) at Texas A&M University Health Science Center (TAMHSC). The agreement ...
-
Exosome Targeting Services at Creative Biolabs Ready to Boost Drug Delivery Research
Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer microenvironment and immune ...
-
Virica Biotech Announces R&D Partnership with Oxford BioMedica
Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene therapies using Virica’s Viral Sensitizers (VSEs™). Ella Korets-Smith, ...
-
Manufacture of Carina’s LGR5 CAR-T has begun with CellVec contracted to produce GMP-grade lentivirus constructs
Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer in late 2022. Lentiviruses are widely used as a tool to deliver genes of interest to cells. In this case, the lentivirus transduces (or inserts) a group of genes to a patient’s ...
-
Matica Biotechnology, Inc. Announces Groundbreaking for New GMP Facility
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, ceremonially broke ground today on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located in Providence Park at ...
-
Matica Biotechnology, Inc. Announces Plans to Construct GMP Facility for Viral Vector Production
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a lease agreement for its GMP production facility located in College Station, TX. Construction of the 25,000 ft2 facility will commence in Q4 2020 and will be dedicated to the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you